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Abstract
Anti-HIV nucleoside monophosphates have limited cellular uptake due to the presence of 
negatively-charged phosphate group. Bis-(cycloSaligenyl) derivatives containing two anti-HIV 
nucleosides, 3′-fluoro-3′-deoxythymidine (FLT) and 3′-azido-3′-deoxythymidine (AZT) were 
synthesized to increase intracellular delivery of nucleoside monophosphates. 2,5-
Bis(hydroxymethylene)benzene-1,4-diol was selected as a monocyclic bidentate scaffold and 
synthesized by three different methods from bis(hydroxymethylene)cyclohexan-1,4-diene-1,4-
diol, or diethyl 2,5-dihydroxyterephthalate. The reaction of the tetraol with 
diisopropylphosphoramidous dichloride in the presence of 2,6-lutidine, followed by conjugation 
reactions with nucleosides (i.e., FLT and AZT) and oxidation afforded symmetrical and 
unsymmetrical bis-(cycloSaligenyl) diphosphate triester products, AZT–AZT, FLT–FLT, and 
FLT–AZT conjugates, in 63–74% overall yields and modest anti-HIV activities (IC50 = 2.8–69.6 
µM).
Keywords
Nucleosides; Bis-(cycloSaligenyl); AZT; FLT; Anti-HIV
Nucleoside analogs are commonly used as antiviral or anticancer agents.1 Cellular 
nucleoside kinases mediate three phosphorylation steps, which convert the nucleosides into 
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their active nucleoside triphosphate analogs (Fig. 1).2 The first phosphorylation to 
nucleoside monophosphate is often the rate-limiting step.3 Negatively charged nucleoside 
monophosphates cannot be used as therapeutic agents because they are unable to cross cell 
membranes efficiently, and they are readily dephosphorylated on cell surfaces and in 
extracellular fluids by non-specific enzymes. Thus, several masked nucleoside phosphate 
mimics have been synthesized as prodrugs with the aim of delivering the corresponding 5′-
monophosphate derivative intracellularly and bypassing the initial phosphorylation step.4 
cycloSaligenyl (cycloSal) pronucleotide system has been introduced as a prodrug approach 
for cellular delivery of several nucleoside monophosphates. The intracellular cleavage of an 
optimal cycloSal pronucleotide to the monophosphate analog is based on intracellular pH-
driven chemical hydrolysis.5
Two or more masking groups are required to generate neutral phosphate triester prodrug of 
nucleosides.6,7 The cycloSal pronucleotide system releases one molecule of drug per 
masking unit (mask to drug ratio, 1:1) as compared to some other pronucleotide delivery 
systems with higher ratios of masking unit, for example, two to four for a single unit of drug 
(2:1–4:1). Ducho et al.8 recently reported synthesis of symmetrical 3,3′-bis-(cyclo-Sal) 
derivatives of 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T) using a bicyclic tetraol to 
deliver two similar nucleosides that led to a significant improvement of anti-HIV activity 
when compared to the parent nucleoside d4T. Gisch et al.9 synthesized 5,5′-bis-cycloSal-
d4T to deliver intracellularly two molecules of d4T-MP that showed improved anti-HIV 
activity when compared to 3,3′-bis-cycloSal-d4T derivatives in thymidine kinase-deficient 
cells.
The reported synthesis of the bis-(cycloSal) derivatives is challenging due to a number of 
synthetic steps for the synthesis of bicyclic tetraol, side reactions between the reactants and 
reagents, tedious purification steps, low yield, and instability of the intermediates. 
Therefore, alternative synthetic methodologies are still required to improve the synthesis of 
bis-(cycloSal) derivatives and their substituted pronucleotides. Furthermore, to the best of 
our knowledge the synthesis of unsymmetrical bis-(cycloSal) derivatives having two 
different nucleosides has not been previously reported. Herein, we report the synthesis of 
novel symmetrical and unsymmetrical derivatives of bis-(cycloSal) derivatives of AZT and 
FLT (Fig. 2) from a new scaffold bis(hydroxymethylene)benzene-1,4-diol (4). It was 
expected that the individual components of multifunctional compounds (nucleoside 
monophosphates) would exhibit biological activity, even enhanced efficacy, when released 
intracellularly by degradative metabolism of the conjugate. Development of resistant virus is 
a serious problem for any antiviral drug. This combination of nucleosides using 
unsymmetrical bis-(cycloSal) may enhance the activity of conjugates against resistant 
strains. The development of resistance to nucleosides would occur at a slower rate than to 
either compound alone.
Bis(hydroxymethylene)benzene-1,4-diol (4) was introduced as a novel monocyclic tetraol 
skeleton for the synthesis of bis-cycloSal derivatives of dideoxynucleosides. The scaffold 
was synthesized by using three different methods and was reacted with phosphorous 
trichloride to afford the cycloSal chlorophosphite. The intermediate was reacted with 
nucleosides under the controlled conditions of stoichiometry and temperature to afford the 
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trivalent phosphite derivatives of nucleosides. Subsequent oxidation using tert-butyl 
hydroperoxide (TBHP) and purification afforded bis-(cycloSal) derivatives of AZT and FLT 
in moderate yields.
Scheme 1 illustrates the synthesis of 2,5-bis(hydroxymethylene) benzene-1,4-diol 4. 2,5-
Bis(methoxycarbonyl)cyclohexa-1,4-diene-1,4-diol 1 was oxidized by refluxing in the 
presence of excess of activated manganese dioxide in toluene to afford the 2,5-
bis(methoxycarbonyl)benzene-1,4-diol 2. Reduction of compound 2 using lithium 
borohydride in methanol and anhydrous diethyl ether or lithium aluminium hydride in THF 
afforded the corresponding tetraol 4 after purification in 44% and 52% overall yields, 
respectively. An alternative method was used to synthesize 4 (60% overall yield) by 
reducing the corresponding diethyl-2,5-dihydroxyterephthalate 3 with BH3·THF under 
anhydrous conditions. In all cases the crude product 4 was purified by column 
chromatography and characterized by NMR and high-resolution time-of-flight electrospray 
mass spectrometry (ESI-TOF), and was used as a scaffold for the synthesis of bis-(cycloSal) 
derivatives.
The reaction of tetraol 4 (0.5 mmol) with phosphorous trichloride (1 mmol) and 2,6-lutidine 
(2 mmol) in anhydrous tetrahydrofuran afforded the bis-(cycloSal chlorophosphite) 5 under 
controlled temperature (−78 °C to −15 °C) (Scheme 2). The addition of 2,6-lutidine (1 
mmol) followed by the dry nucleoside (AZT or FLT) (1 mmol), to the same reaction mixture 
under the controlled conditions of the temperature (−55 °C to −10 °C) afforded the 
corresponding symmetrical phosphite triester derivatives 6a and 6b. The oxidation of 6a and 
6b by TBHP and purification by preparative HPLC afforded the symmetrical bis-(cycloSal) 
phosphate triester derivatives FLT–FLT (7a, 74%) and AZT–AZT (7b, 71%) as a 
diastereomeric mixture. The separation of diastereomers was not possible for 7a and 7b.
In a separate reaction, tetraol 4 was reacted with phosphorus trichloride in the presence of 
2,6-lutidine at −78 °C in anhydrous tetrahydrofuran to afford intermediate 5 as described 
above (Scheme 2). Then the reaction temperature was kept at −55 °C using dry ice and 
acetone. To the reaction mixture was added 2,6-lutidine (1 mmol) followed by dry 
nucleoside AZT (0.5 mmol) (Scheme 3). The reaction was continued for 85 min with steady 
increase of the temperature to −50 °C. The second nucleoside FLT (0.5 mmol) was added 
and the temperature was raised to −10 °C over a period of 95 min. Oxidation with TBHB 
and HPLC purification afforded the unsymmetrical bis-(cycloSal) phosphate triester of 
AZT–FLT 10 (63%) as a diastereomeric mixture (Scheme 3).
Compound 7b showed only modest antiviral activity (IC50 = 69.6 µM), significantly lower 
than that of the parent nucleoside, FLT (IC50 = 0.8 µM), when tested using a single-round 
infection assay10 using HIV-1 ×4 tropic strains and transformed HeLa cells expressing HIV 
receptors (CD4) and coreceptors (CXCR4). Compounds 7a and 10 exhibited IC50 values of 
12.3 and 2.8 µM, respectively, while control scaffold 4 had an IC50 value of 86.5 µM. These 
data suggest that the presence of both AZT and FLT in the same conjugate generates higher 
anti-HIV activity as was shown in 10 when compared with 7a and 7b. There are several 
factors which determine in vitro anti-HIV activity of each analog that may include stability, 
rate of cellular uptake, nature of nucleoside, and extracellular and intracellular rate of 
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hydrolysis. Structure–function analysis revealed that the anti-HIV activity of bis-
(cycloSaligenyl) diphosphate triester products, AZT–AZT, FLT–FLT, and FLT–AZT was 
clearly dependent on the nature of the nucleoside in the conjugate. These results suggest that 
the increased inhibition by 10 may be due to the higher cellular uptake, enhanced 
intracellular release of FLT and AZT, and/or stability of the conjugate when compared with 
7a and 7b. The extracellular hydrolysis of phosphate triester derivatives of FLT and AZT 
has been previously reported.11 The partial or complete premature extracellular hydrolysis 
of the bis-(cycloSal) group in all analogs may produce negatively-charged phosphate 
derivatives with limited cellular uptake and decreased anti-HIV activity. The rate of 
extracellular hydrolysis remains to be determined to compare the stability of the conjugates. 
Cytotoxicity assays revealed that compounds were not cytotoxic at the highest concentration 
tested (CC50 >100 µM).
To the best of our knowledge, this is first report on the synthesis of symmetrical and 
unsymmetrical bis-(cycloSal) derivatives of FLT and AZT from a monocyclic scaffold, 
bis(hydroxymethylene)benzene-1,4-diol. This one-pot strategy from a tetraol to the target 
compounds minimizes side reactions and eliminates the need for the purification of 
intermediates. The synthesis of these compounds provides insights for design of more 
optimal scaffolds of bis-(cycloSal) nucleoside derivatives with higher stability, cellular 
uptake, and anti-HIV activity.
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Figure 1. 
Nucleoside phosphorylation and cycloSal delivery system of nucleoside monophosphate.5
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Figure 2. 
Symmetrical and unsymmetrical derivatives of bis-(cycloSal) derivatives of AZT and FLT.
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Scheme 1. 
Synthesis of 2,5-bis(hydroxymethylene)benzene-1,4-diol 4.
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Scheme 2. 
Synthesis of symmetrical bis-(cycloSal) derivatives of AZT–AZT 7a and FLT–FLT 7b.
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Scheme 3. 
Synthesis of unsymmetrical derivative of bis-(cycloSal) analog of FLT and AZT (10).
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